PSIAC
Sad Pill Bild Bildrechte: © spinetta / Fotolia

Oops!

Sie verwenden eine veraltete Version Ihres Internetbrowsers und können nicht auf die Inhalte der Seite zugreifen.
Bitte aktualisieren Sie Ihre Browserversion.

PSIAC

Literaturverzeichnis

Erweiterte Suche
Valdes M. J Affect Disord. Mar 2019; 246: 861-866 Pubmed [9888]
Vale JA. Lancet. Jun 1991; 337(8756): 1552 Pubmed [1279]
Valin N. J Int Assoc Physicians AIDS Care (Chic). Mar 2009; 8(2): 113-21 Pubmed [6380]
Valk-Swinkels CG. Ned Tijdschr Geneeskd. Jan 2013; 157(28): A5667 Pubmed [6215]
Vallée A. Aging (Albany NY). Feb 2020; 12(3): 3095-3113 Pubmed [11454]
Vallejo R. Pain Physician. Jul 2011; 14(4): E343-60 Pubmed [3301]
Valsalan VC. Br Med J (Clin Res Ed). Jul 1982; 285(6337): 261-2 Pubmed, Volltext [6788]
Van Berkel MA. Pharmacotherapy. Jun 2013; 33(6): e96-100 Pubmed [6132]
van Breemen RB. Fitoterapia. Jan 2011; 82(1): 38-43 Pubmed [12297]
van Breemen RB. J Agric Food Chem. May 2020; 68(18): 5212-5220 Pubmed [9109]
Van Cauwenberge P. Expert Opin Pharmacother. Aug 2004; 5(8): 1807-13 Pubmed [14371]
van Dalem J. BMJ. Jul 2016; 354: i3625 Pubmed, Volltext, DOI [9026]
Van de Velde V. Drugs R D. Mar 2013; 13(1): 43-51 Pubmed [14120]
van de Wetering-Krebbers SF. Drug Metab Dispos. Apr 2011; 39(4): 580-90 Pubmed [250]
van den Bemt PM. Pharm World Sci. Oct 2002; 24(5): 201-4 Pubmed [11830]
van den Berg MJ. Am J Ther. Jan 2016; 23(1): e246-8 Pubmed [1592]
Van den Bergh A. Clin Pharmacokinet. Sep 2020; 59(9): 1149-1160 Pubmed [11495]
Van der Auwera P. J Antimicrob Chemother. Nov 1993; 32 Suppl B: 103-15 Pubmed [5908]
van der Bol JM. Clin Cancer Res. Jan 2010; 16(2): 736-42 Pubmed [5010]
Van der Heijden KB. J Am Acad Child Adolesc Psychiatry. Feb 2007; 46(2): 233-41 Pubmed [11710]
van der Klauw MM. Arch Intern Med. Feb 1999; 159(4): 369-74 Pubmed [9089]
van der Kuy PH. BMJ. Feb 1998; 316(7129): 441 Pubmed, Volltext [1954]
van der Lee M. Antivir Ther. Jan 2007; 12(7): 1127-32 Pubmed [6482]
van der Lee MJ. Antimicrob Agents Chemother. Nov 2007; 51(11): 4098-104 Pubmed, Volltext, DOI [10143]
van der Lee MJ. Clin Pharmacol Ther. Aug 2006; 80(2): 159-68 Pubmed [8755]
van der Sandt IC. AIDS. Mar 2001; 15(4): 483-91 Pubmed [4997]
van der Velden W. Neth J Med. May 2008; 66(5): 204-6 Pubmed [5870]
van der Watt JJ. Int J Tuberc Lung Dis. Nov 2015; 19(11): 1312-9 Pubmed [9404]
van der Weide K. J Clin Psychopharmacol. Jun 2015; 35(3): 228-36 Pubmed [193]
van der Zalm IJB. J Med Case Rep. Jun 2020; 14(1): 83 Pubmed [11309]
van Dijkman SC. Br J Clin Pharmacol. Jan 2018; 84(1): 97-111 Pubmed, Volltext, DOI [9427]
Van Es MA. Amyotroph Lateral Scler Frontotemporal Degener. Nov 2020; 21(7-8): 584-592 Pubmed [11457]
van Giersbergen PL. Clin Pharmacol Ther. Mar 2007; 81(3): 414-9 Pubmed [4289]
van Giersbergen PL. Int J Clin Pharmacol Ther. Mar 2006; 44(3): 113-8 Pubmed [4287]
van Gorp F. Br J Clin Pharmacol. Mar 2012; 73(3): 402-10 Pubmed [13801]
van Haarst AD. Clin Pharmacol Ther. Nov 1998; 64(5): 542-6 Pubmed [5324]
van Harten et al. Eur Neuropsychopharmacol (1992) 2, 381 [1462]
van Harten J. Clin Pharmacokinet. Jan 1995; 29 Suppl 1: 1-9 Pubmed [325]
van Harten J. Clin Pharmacol Ther. Oct 1992; 52(4): 427-35 Pubmed [1457]
van Heeswijk RP. Antivir Ther. Jan 2013; 18(4): 553-60 Pubmed [6322]
van Heeswijk RP. J Antimicrob Chemother. Sep 2014; 69(9): 2310-8 Pubmed [5184]
van Heeswijk RP. J Clin Pharmacol. Jul 2006; 46(7): 758-67 Pubmed [461]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010;. [7391]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010;. [7392]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010;. [7393]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7394]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7395]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7396]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7397]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7398]
Van Heeswijk, R.; Boogaerts, G.; De Paepe, E.; Van Solingen-Ristea, R.; Garg, V.; Beumont, M., The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy; Boston, MA. June 23–24, 2010. [7399]
van Helvoort M. Int Clin Psychopharmacol. Sep 2019; 34(5): 269-272 Pubmed [9131]
van Hoppe S. Pharmacol Res. Aug 2019; 146: 104297 Pubmed [11487]
van Hoppe S. Pharmacol Res. Jun 2017; 120: 43-50 Pubmed [7756]
Van Kammen DP. Psychopharmacologia. Nov 1975; 44(3): 215-24 Pubmed [1743]
van Kan HJ. Biopharm Drug Dispos. Apr 2008; 29(3): 139-44 Pubmed [11375]
van Laar MW. Psychopharmacology (Berl). Aug 2002; 162(4): 351-63 Pubmed [11246]
van Leeuwen DJ. Ned Tijdschr Geneeskd. Mar 1986; 130(12): 548-50 Pubmed [6091]
Van LM. J Psychopharmacol. Nov 2006; 20(6): 834-41 Pubmed [13738]
van Luin M. AIDS. May 2010; 24(8): 1223-6 Pubmed [6421]
van Luin M. J Acquir Immune Defic Syndr. Sep 2010; 55(1): 82-6 Pubmed [7378]
van Luin M. J Clin Pharmacol. Oct 2009; 49(10): 1220-7 Pubmed [2953]
van Maarseveen EM. AIDS Patient Care STDS. Oct 2012; 26(10): 568-81 Pubmed [8981]
van Meerten E. Drug Saf. Mar 1995; 12(3): 168-82 Pubmed [7341]
van Nuland M. Prostate Cancer Prostatic Dis. Jun 2020; 23(2): 244-251 Pubmed [12403]
van Praag HM. Biol Psychiatry. Feb 1987; 22(2): 205-12 Pubmed [8281]
Van Rooij J. Br J Clin Pharmacol. Jun 1993; 35(6): 661-3 Pubmed, Volltext, DOI [8584]
van Schaik RH. Invest New Drugs. Dec 2005; 23(6): 513-22 Pubmed [13877]
van Seyen M. Clin Pharmacol Ther. Nov 2019; 106(5): 1093-1098 Pubmed [8058]
Van Slooten AD. DICP. Jun 1991; 25(6): 578-82 Pubmed [5833]
Van Strater AC. Int Clin Psychopharmacol. Mar 2012; 27(2): 121-4 Pubmed [1129]
van Waterschoot RA. Br J Pharmacol. Jul 2010; 160(5): 1224-33 Pubmed, Volltext, DOI [8777]
van Wieringen A. Clin Pharmacokinet. Apr 1990; 18(4): 332-8 Pubmed [2451]
van Wieringen A. Neurology. Sep 1983; 33(9): 1227-8 Pubmed [9275]
van Zuilekom S. Tijdschr Psychiatr. Jan 2013; 55(12): 955-9 Pubmed [6999]
van Zwieten PA. Arch Int Pharmacodyn Ther. Mar 1975; 214(1): 12-30 Pubmed [1941]
Vanakoski J. Eur J Clin Pharmacol. Jan 1996; 50(6): 501-8 Pubmed [1877]
Vance KM. Nutrition. Jul 2014; 30(7-8 Suppl): S37-42 Pubmed [13708]
Vandel et al. Pharm Res 1995;31(6):347-353 [1025]
Vandel et al. Therapie (1990) 45, 21 [1027]
Vandel P. Encephale. Jan 1999; 25(1): 67-71 Pubmed [3182]
Vandel P. Encephale. Nov 1999; 25(6): 672-3 Pubmed [10122]
Vandel P. Hum Psychopharmacol. Jul 2004; 19(5): 293-8 Pubmed [8213]
Vandel S. Pharmacol Res. Jun 1995; 31(6): 347-53 Pubmed [1480]
Vandel S. Ther Drug Monit. Jan 1988; 10(4): 386-9 Pubmed [2421]
Vandel. Therapie (1990) 45, 21 [544]
VandenBrink BM. Drug Metab Dispos. Jan 2012; 40(1): 47-53 Pubmed [3488]
Vandenbussche C. Arch Toxicol. Apr 2018; 92(4): 1539-1550 Pubmed [7889]
Vandevelde C. Pharmacotherapy. Jan 1991; 11(1): 88-9 Pubmed [6210]
VanLandingham KE. J Clin Pharmacol. Oct 2020; 60(10): 1304-1313 Pubmed, Volltext, DOI [9843]
VARAGIC V. Arch Int Pharmacodyn Ther. Apr 1958; 114(3-4): 426-34 Pubmed [9402]
Varanese S. Mov Disord. Mar 2010; 25(4): 508-10 Pubmed [9917]
Vardar MK, Kovalak EE. Bagcilar Med Bul. Sep 2022; 7: 288–290 Pubmed [13449]
Varhe A. Br J Clin Pharmacol. Apr 1996; 41(4): 319-23 Pubmed, Volltext, DOI [2398]
Varhe A. Br J Clin Pharmacol. Oct 1996; 42(4): 465-70 Pubmed, Volltext, DOI [2394]
Varhe A. Clin Pharmacol Ther. Apr 1996; 59(4): 369-75 Pubmed [2400]
Varhe A. Clin Pharmacol Ther. Dec 1994; 56(6 Pt 1): 601-7 Pubmed [2396]
Varis et al. Clin Pharmacol Therap 2000;68(5):487-494 [2972]
Varis T. Clin Pharmacol Ther. Nov 2000; 68(5): 487-94 Pubmed [4493]
Varsaldi F. Eur J Clin Pharmacol. Sep 2006; 62(9): 721-6 Pubmed [113]